|
 |
|
|||||||
|
|||||||||
Copyright © 1983 by American Society of Health-System Pharmacists
Articles |
Exposure of hospital workers to airborne antineoplastic agents
Practices for handling antineoplastic drugs were surveyed, and ambient-air sampling for four antineoplastic agents was conducted in outpatient oncology clinics. A questionnaire was administered in 1981 to the nurse or pharmacist in charge of drug preparation at 10 hospital oncology clinics. At three sites, air samples were collected during working hours in medication-preparation rooms and nearby offices. The air-sampling pumps contained filters at breathing-zone height; room air was drawn through each filter for 40 hours. Extracts from the filters were assayed by high-performance liquid chromatography (HPLC) for fluorouracil and cyclophosphamide in seven sets of samples and methotrexate and doxorubicin in five sets of samples. Mass spectrometry (MS) was used to confirm detection of fluorouracil. Total use of each monitored drug was recorded at each site. Nine clinics had no ventilation hood, and drugs were prepared by nurses in eight clinics. Routine use of gloves (three clinics) and masks (one clinic) was uncommon, and wastes were disposed of in uncovered receptacles in four of the clinics. Eating and drinking occurred in seven of the preparation rooms. At the main air-sampling site, fluorouracil (0.12-82.26 ng/cu m) was detected in air during 200 of the 320 hours monitored. Cyclophosphamide (370 ng/cu m) was present during 80 hours. In the two other sites, fluorouracil was detected by HPLC but not confirmed by MS, and no cyclophosphamide was detected. No detectable amounts of methotrexate and doxorubicin were present. Fluorouracil was the most frequently used drug, and cyclophosphamide was second. Results suggest that personnel handling antineoplastic drugs are subject to potential systemic absorption of these agents by inhalation.
This article has been cited by other articles:
|
|
 |
|
  E. Green, M. Johnston, M. Trudeau, L. Schwartz, S. Poirier, G. Macartney, and D. Milliken Safe Handling of Parenteral Cytotoxics: Recommendations for Ontario J. Oncol. Pract, September 1, 2009; 5(5): 245 - 249. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Section 10 Chemical contamination monitoring Journal of Oncology Pharmacy Practice, September 1, 2007; 13(3_suppl): 44 - 48. [PDF]
|
|
|
|
 |
|
 B. R. Harrison, B. G. Peters, and M. R. Bing Comparison of surface contamination with cyclophosphamide and fluorouracil using a closed-system drug transfer device versus standard preparation techniques. Am. J. Health Syst. Pharm., September 15, 2006; 63(18): 1736 - 1744. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. FRANSMAN, R. VERMEULEN, and H. KROMHOUT Occupational Dermal Exposure to Cyclophosphamide in Dutch Hospitals: A Pilot Study Ann. Hyg., April 1, 2004; 48(3): 237 - 244. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. R. Ferguson Occupational health and staff monitoring: A genetic toxicologist's viewpoint Journal of Oncology Pharmacy Practice, January 1, 1995; 1(3): 49 - 54. [Abstract] [PDF]
|
|
|
|
 |
|
 S. Burgaz, Y.N. Ozdamar, and A.E. Karakaya A Signal Assay for the Detection of Genotoxic Compounds: Application on the Urines of Cancer Patients on Chemotherapy and of Nurses Handling Cytotoxic Drugs Human and Experimental Toxicology, November 1, 1988; 7(6): 557 - 560. [Abstract] [PDF]
|
|
|
|
 |
|
 Council on Scientific Affairs Guidelines for Handling Parenteral Antineoplastics JAMA, March 15, 1985; 253(11): 1590 - 1592. [Abstract] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |